Cargando…

Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer

Nearly one-third of patients with high-grade serous ovarian cancer (HGSC) do not respond to initial treatment with platinum-based therapy. Genomic and clinical characterization of these patients may lead to potential alternative therapies. Here, the objective is to classify non-responders into subse...

Descripción completa

Detalles Bibliográficos
Autores principales:	McDonald, Megan E., Salinas, Erin A., Devor, Eric J., Newtson, Andreea M., Thiel, Kristina W., Goodheart, Michael J., Bender, David P., Smith, Brian J., Leslie, Kimberly K., Gonzalez-Bosquet, Jesus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429334/ https://www.ncbi.nlm.nih.gov/pubmed/30866519 http://dx.doi.org/10.3390/ijms20051175

Ejemplares similares

Creation and validation of models to predict response to primary treatment in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2021)

Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer
por: Newtson, Andreea, et al.
Publicado: (2021)

Prediction of chemo-response in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2016)

Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers
por: Devor, Eric J., et al.
Publicado: (2017)

Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy
por: Lyons, Yasmin A, et al.
Publicado: (2020)

Population Substructure Has Implications in Validating Next-Generation Cancer Genomics Studies with TCGA
por: Miller, Marina D., et al.
Publicado: (2019)

A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables
por: Salinas, Erin A., et al.
Publicado: (2019)

Identification of Novel lncRNAs in Ovarian Cancer and Their Impact on Overall Survival
por: Cardillo, Nicholas, et al.
Publicado: (2021)

Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior
por: Reyes, Henry D., et al.
Publicado: (2019)

Using Genomic Variation to Distinguish Ovarian High-Grade Serous Carcinoma from Benign Fallopian Tubes
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2022)

An integrated prediction model of recurrence in endometrial endometrioid cancers
por: Miller, Marina D, et al.
Publicado: (2019)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
por: BRACHOVA, PAVLA, et al.
Publicado: (2014)

Microbial Communities in Gynecological Cancers and Their Association with Tumor Somatic Variation
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2023)

Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2021)

Integration of Genomic and Clinical Retrospective Data to Predict Endometrioid Endometrial Cancer Recurrence
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2022)

Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing
por: Bi, Jianling, et al.
Publicado: (2021)

Disparity of ovarian cancer survival between urban and rural settings
por: Ulmer, Keely Krolikowski, et al.
Publicado: (2022)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
por: Bi, Jianling, et al.
Publicado: (2021)

A nuclear polymorphism at the 8q24 region is associated with improved survival time and chemo-response in high-grade serous ovarian cancer
por: Ikoma, Danielle, et al.
Publicado: (2021)

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer
por: Bi, Jianling, et al.
Publicado: (2022)

The Synthetic Curcumin Analog HO-3867 Rescues Suppression of PLAC1 Expression in Ovarian Cancer Cells
por: Devor, Eric J., et al.
Publicado: (2021)

hCG production by mucinous adenocarcinoma of the ovary in a reproductive aged woman
por: Wagner, Vincent, et al.
Publicado: (2018)

The miR-503 cluster is coordinately under-expressed in endometrial endometrioid adenocarcinoma and targets many oncogenes, cell cycle genes, DNA repair genes and chemotherapy response genes
por: Devor, Eric J, et al.
Publicado: (2018)

Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
por: Österberg, Lovisa, et al.
Publicado: (2009)

Role of Neoadjuvant Chemotherapy in Ovarian Serous Cancer Followed by Debulking
por: Chauhan, Sonali, et al.
Publicado: (2022)

Malignant struma ovarii with insular carcinoma: A case report and literature review
por: Williams, Heather, et al.
Publicado: (2016)

FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways
por: Dixit, Garima, et al.
Publicado: (2023)

Placenta-Specific Protein 1: A Potential Key to Many Oncofetal-Placental OB/GYN Research Questions
por: Devor, Eric J., et al.
Publicado: (2014)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
por: Brachova, Pavla, et al.
Publicado: (2013)

Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
por: Vanguri, Rami, et al.
Publicado: (2022)

Tissue Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant Chemotherapy
por: Khandakar, Binny, et al.
Publicado: (2014)

Uterine Clostridium perfringens infection related to gynecologic malignancy
por: Kremer, Kevin M., et al.
Publicado: (2017)

Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
por: Bock, Annika J., et al.
Publicado: (2011)

Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182
por: DEVOR, ERIC J., et al.
Publicado: (2016)

Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance
por: Ricciardelli, Carmela, et al.
Publicado: (2017)

Role of metadherin in estrogen-regulated gene expression
por: Li, Yujun, et al.
Publicado: (2017)

miR-888: A Novel Cancer-Testis Antigen that Targets the Progesterone Receptor in Endometrial Cancer()()
por: Hovey, Adriann M., et al.
Publicado: (2015)

Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
por: Ducie, Jennifer, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_104vj638kh4mb8tn0h0jc5hnjc